<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="336668">
  <stage>Registered</stage>
  <submitdate>25/08/2011</submitdate>
  <approvaldate>26/08/2011</approvaldate>
  <actrnumber>ACTRN12611000916943</actrnumber>
  <trial_identification>
    <studytitle>Multicentre randomised controlled trial of minimally-invasive surfactant therapy in preterm infants 25-28 weeks gestation on continuous positive airway pressure</studytitle>
    <scientifictitle>Multicentre randomised controlled trial in preterm infants 25-28 weeks gestation on continuous positive airway pressure of the effect of minimally-invasive surfactant therapy in comparison to standard care (continuation of CPAP) on the incidence of the composite outcome of death or physiological BPD.</scientifictitle>
    <utrn />
    <trialacronym>OPTIMIST-A</trialacronym>
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Neonatal respiratory distress syndrome</healthcondition>
    <healthcondition>Bronchopulmonary dysplasia</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Other respiratory disorders / diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Complications of newborn</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Minimally invasive surfactant therapy - delivery of exogenous surfactant to the lung via brief catheterisation of the trachea with an instillation catheter in a preterm infant who is being supported with continuous positive airway pressure (CPAP) via nasal prongs or mask. The poractant surfactant dose will be 200 mg/kg, administered over 15 - 30 seconds. Total duration of the procedure will be less than 5 minutes, followed by reinstitution of CPAP. Only a single dose will be given within the first 6 hours of life. 

This intervention will be given throughout the course of the trial, which is expected to last 5 years.</interventions>
    <comparator>Continued treatment with nasal CPAP delivered by prongs or mask. This is the standard control treatment. After randomisation, infants will receive a sham treatment from a treatment team not engaged in clinical care. This will not involve removal of prongs or discontinuation of CPAP but will require setting up intubation equipment, screening the baby, testing suction unit, repositioning of the baby and changing the baby's monitoring.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Treatment: Devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Composite outcome of death by 36 weeks or physiological bronchopulmonary dysplasia (BPD). Physiological BPD is assessed at 36 weeks post-menstrual age, and is defined as either need for respiratory support (intubation / CPAP / high flow nasal cannula &gt; 2 L/min) or need for FiO2 &gt;=0.3 or failure of a room air trial conducted at 36 weeks post-menstrual age. This will be assessed by the research nurse at each centre.</outcome>
      <timepoint>36 weeks post-menstrual age</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Mortality</outcome>
      <timepoint>By 36 weeks post-menstrual age and throughout hospitalisation.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Major morbidity, defined as one or more of BPD, grade III or IV intraventricular haemorrhage, periventricular leukomalacia or retinopathy of prematurity &gt; stage 2. Screening for intraventricular haemorrhage, periventricular leukomalacia and retinopathy of prematurity will be performed as routine care, and the results taken from the medical record.</outcome>
      <timepoint>During first hospitalisation</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pneumothorax, as documented in medical record.</outcome>
      <timepoint>During first hospitalisation</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Duration of respiratory support, defined as cumulative hours of all episodes of intubation, nasal CPAP and high flow nasal cannula oxygen (flow rate &gt;= 2 litres/min). This information will be derived from medical record or unit database.</outcome>
      <timepoint>During first hospitalisation</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Gestational age 25-28 completed weeks 2. Requiring CPAP with signs of early respiratory distress. 3. CPAP pressure of 5-8 cm H2O and FiO2 &gt;=0.30.  4. Less than 6 hours of age. 5. Agreement of the Treating Physician in charge of the infants care. 6. Signed parental consent.</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>Hours</inclusiveminagetype>
    <inclusivemaxage>6</inclusivemaxage>
    <inclusivemaxagetype>Hours</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Previously intubated, or in imminent need of intubation because of respiratory distress, apnoea or persistent acidosis.
2. Congenital anomaly or condition that might adversely affect breathing.
3. Identifiable alternative cause for respiratory distress (e.g. congenital pneumonia or pulmonary hypoplasia).
4. Lack of availability of an OPTIMIST treatment team.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Preterm infants of gestation 25 weeks 0 days - 28 weeks 6 days who fulfill the entry criteria will be enrolled once written parental consent has been obtained by the treating clinicians. The infant will be randomised by the OPTIMIST Treatment Team, after handover of care from the treating clinicians. A web-based central randomisation program will allocate infants into “surfactant via MIST” and “standard care” groups, with an allocation ratio of 1:1. Twins and higher order multiples will be randomised independently.</concealment>
    <sequence>The randomisation schedule and web-based service will be provided by the Clinical Epidemiology and Biostatistics Unit at the Murdoch Childrens Research Institute. The randomisation will be in randomly permuted blocks of variable length, stratified by study centre, and by gestational age. There will be two gestational age strata; 25-26 weeks and 27-28 weeks.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>21/11/2011</anticipatedstartdate>
    <actualstartdate>16/12/2011</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>606</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia,Outside</recruitmentcountry>
    <recruitmentstate>TAS,VIC</recruitmentstate>
    <hospital>Royal Hobart Hospital - Hobart</hospital>
    <hospital>The Royal Women's Hospital - Parkville</hospital>
    <hospital>Monash Medical Centre - Clayton campus - Clayton</hospital>
    <hospital>Mercy Hospital for Women - Heidelberg</hospital>
    <postcode>7000 - Hobart</postcode>
    <postcode>3052 - Parkville</postcode>
    <postcode>3168 - Clayton</postcode>
    <postcode>3081 - Heidelberg Rgh</postcode>
    <countryoutsideaustralia>
      <country>United States of America</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States of America</country>
      <state>Connecticut</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States of America</country>
      <state>Hawaii</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States of America</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States of America</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States of America</country>
      <state>West Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Ankara</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Bursa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovenia</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Otago</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Menzies Institute of Medical Research University of Tasamania</primarysponsorname>
    <primarysponsoraddress>Liverpool St
Hobart
TAS 7000</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Royal Hobart Hospital Research Foundation</fundingname>
      <fundingaddress>Royal Hobart Hospital
Liverpool St
Hobart
TAS 7000</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Health and Medical Research Council</fundingname>
      <fundingaddress>Canberra</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>University</sponsortype>
      <sponsorname>University of Tasmania</sponsorname>
      <sponsoraddress>Sandy Bay
TAS 7005</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Hospital</othercollaboratortype>
      <othercollaboratorname>Royal Hobart Hospital</othercollaboratorname>
      <othercollaboratoraddress>Liverpool St
Hobart 
TAS 7000</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Hospital</othercollaboratortype>
      <othercollaboratorname>Royal Women's Hospital</othercollaboratorname>
      <othercollaboratoraddress>Flemington Rd
Parkville
VIC 3052</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Does administration of exogenous surfactant using a minimally-invasive technique improve outcome in preterm infants 25-28 weeks gestation treated with continuous positive airway pressure (CPAP)? A multicentre, randomised, masked, controlled trial will be conducted in inborn preterm infants 25-28 weeks gestation, aged less than 6 hours, requiring CPAP because of respiratory distress, with an FiO2 of &gt;=0.3  and CPAP pressure 5-8. Infants randomised to surfactant treatment will receive 200 mg/kg of poractant alfa (Curosurf) administered under direct laryngoscopy using a surfactant instillation catheter, followed by reinstitution of CPAP. Controls will continue on CPAP. The intervention will be masked from the clinical team. Care thereafter will be as per usual in both groups, other than the requirement to adhere to intubation criteria. The primary outcome will be incidence of death or BPD. Secondary outcomes will include incidence of death, major neonatal morbidities (BPD, intraventricular haemorrhage, periventricular leukomalacia, retinopathy of prematurity, necrotising enterocolitis), pneumothorax and patent ductus arteriosus; need for intubation and surfactant therapy; durations of mechanical respiratory support, intubation, CPAP, intubation and CPAP, high flow nasal cannula (HFNC), oxygen therapy, intensive care stay and hospitalisation; hospitalisation cost; applicability and safety of the MIST procedure; and outcome at 2 years. The sample size will be 303/group, allowing detection of a 33% difference in the primary outcome with 90% power. The trial commenced at Royal Hobart Hospital December 2011 and Royal Women's Hospital during 2012, and will ultimately be conducted over 5 years in multiple centres nationally and overseas.</summary>
    <trialwebsite>http://www.menzies.utas.edu.au/optimist-trials</trialwebsite>
    <publication>Dargaville PA, Aiyappan A, De Paoli AG, et al. Minimally-invasive surfactant therapy in preterm infants on continuous positive airway pressure. Arch Dis Child Fetal Neonatal Ed 2012; doi: 10.1136/archdischild-2011-301314

Dargaville PA, Aiyappan A, Cornelius A, et al. Preliminary evaluation of a new technique of minimally invasive surfactant therapy. Arch Dis Child Fetal Neonatal Ed 2011;96:F243-F248.

Dargaville PA, Aiyappan A, De Paoli AG, et al. CPAP failure in preterm infants defines a group at high risk of adverse outcome. PAS abstract 2011; 752879

Dargaville PA. Innovation in Surfactant Therapy I: Surfactant Lavage and Surfactant Administration by Fluid Bolus Using Minimally Invasive Techniques. Neonatology 2012;101: 326-336</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Tasmanian Human Research Ethics Committee</ethicname>
      <ethicaddress>Office of Research Services
University of Tasmania
Private Bag 1
Hobart
Tasmania
7001</ethicaddress>
      <ethicapprovaldate>6/06/2011</ethicapprovaldate>
      <hrec>H11615</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Women's Hospital Research Committee</ethicname>
      <ethicaddress>Flemington Road
Parkville
Victoria 3052</ethicaddress>
      <ethicapprovaldate>17/08/2011</ethicapprovaldate>
      <hrec>11/39</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Monash Health HREC B</ethicname>
      <ethicaddress>Monash Health
Monash Medical Centre
246 Clayton Road
Clayton
Victoria   3168</ethicaddress>
      <ethicapprovaldate>23/12/2013</ethicapprovaldate>
      <hrec>13362B</hrec>
      <ethicsubmitdate>17/10/2013</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Mercy Health Human Research Ethics Committee</ethicname>
      <ethicaddress>Mercy Health
Level 2, 12 Shelley St.,
Richmond
Victoria    3121</ethicaddress>
      <ethicapprovaldate>31/03/2013</ethicapprovaldate>
      <hrec>R13/10</hrec>
      <ethicsubmitdate>1/03/2013</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Auckland District Health Board Research Review Committee</ethicname>
      <ethicaddress>Auckland City Hospital
PB 92024
Grafton
Auckland</ethicaddress>
      <ethicapprovaldate>4/04/2014</ethicapprovaldate>
      <hrec>13/NTB/126</hrec>
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>NorthShore University HealthSystem First Friday Institutional Review Board</ethicname>
      <ethicaddress>1001 University Place
Evanston
IL  60201</ethicaddress>
      <ethicapprovaldate>12/06/2013</ethicapprovaldate>
      <hrec>EH 13-047</hrec>
      <ethicsubmitdate>12/07/2012</ethicsubmitdate>
      <ethiccountry>United States of America</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>The Cooper Health System Institutional Review Board</ethicname>
      <ethicaddress>E&amp;R Building rooms 128 and 288
401 Haddon Ave.,
Camden
New Jersey   08103</ethicaddress>
      <ethicapprovaldate>4/04/2015</ethicapprovaldate>
      <hrec>RP# 13-033</hrec>
      <ethicsubmitdate />
      <ethiccountry>United States of America</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Western Institutional Review Board</ethicname>
      <ethicaddress>1019 39th Ave., SE Suite 120
Puyallup
WA  98374-2115</ethicaddress>
      <ethicapprovaldate>6/10/2014</ethicapprovaldate>
      <hrec>1147151</hrec>
      <ethicsubmitdate />
      <ethiccountry>United States of America</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Clinical Trials Department Ministry of Health</ethicname>
      <ethicaddress>PO B1176
Jerusalem 9101002</ethicaddress>
      <ethicapprovaldate>20/11/2014</ethicapprovaldate>
      <hrec>20140110</hrec>
      <ethicsubmitdate />
      <ethiccountry>Israel</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Peter Dargaville</name>
      <address>Royal Hobart Hospital
Liverpool St
Hobart
TAS 7000</address>
      <phone>+61 3 62227546</phone>
      <fax />
      <email>peter.dargaville@dhhs.tas.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Peter Dargaville</name>
      <address>Royal Hobart Hospital
Liverpool St
Hobart
TAS 7000</address>
      <phone>+61 3 62227546</phone>
      <fax />
      <email>peter.dargaville@dhhs.tas.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Ms. Karen Butterley</name>
      <address>Royal Hobart Hospital
Liverpool St
Hobart
TAS 7000</address>
      <phone>+61 3 62227546</phone>
      <fax />
      <email>karen.butterley@dhhs.tas.gov.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Peter Dargaville</name>
      <address>Royal Hobart Hospital
Liverpool Street
Hobart
Tasmania
7000</address>
      <phone>+61 3 62227546</phone>
      <fax />
      <email>peter.dargaville@dhhs.tas.gov.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>